CLAIMS

What is claimed is:

1. A pharmaceutical composition comprising an anti-LAG-3 antibody and an anti-PD-1 antibody, wherein
the pharmaceutical composition comprises a pharmaceutically-acceptable carrier, 80 mg of an anti-LAG-3 antibody and 240 mg of an anti-PD-1 antibody;
wherein the anti-PD-1 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:19 and 21, respectively; and
the anti-LAG-3 antibody comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:3 and 5, respectively.

2. The pharmaceutical composition according to claim 1, wherein the anti-LAG-3 antibody is a human antibody.

3. The pharmaceutical composition according to claim 1 or 2, wherein the anti-PD-1 antibody is a human antibody.

4. The pharmaceutical composition according to any one of claims 1-3, wherein the anti-LAG-3 antibody is an IgG1, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, or IgE isotype.

5. The pharmaceutical composition according to any one of claims 1-4, wherein the anti-PD-1 antibody is an IgG1, IgG2, IgG3, IgG4, IgM, IgAl, IgA2, IgAsec, IgD, or IgE isotype.

6. The pharmaceutical composition according to any one of claims 1-5, wherein the anti-LAG-3 antibody and anti-PD-1 antibody are human, IgG4 isotype antibodies.

7. The pharmaceutical composition according to any one of claims 1-6, wherein the anti-LAG-3 antibody comprises heavy and light chains comprising the sequences set forth in SEQ ID NOs:1 and 2, respectively.

8. The pharmaceutical composition according to any one of any one of claims 1-7, wherein the anti-PD-1 antibody comprises heavy and light chains comprising the sequences as set forth in SEQ ID NOs:17 and 18, respectively.

9. The pharmaceutical composition according to any one of claims 1-8, which is formulated for parenteral administration.

10. The pharmaceutical composition according to any one of claims 1-9, which is formulated for injection or infusion.

11. The pharmaceutical composition according to any one of claims 1-10, which is formulated for intravenous administration.

12. The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutically-acceptable carrier is a sterile liquid.

13. The pharmaceutical composition of any one of claims 1-12, wherein the pharmaceutically-acceptable carrier is water, an oil, aqueous solution saline, aqueous dextrose, or a glycerol solution.